Form 4: BioMarin Director Ian Clark Receives Stock Grant

Director Ian T. Clark acquired 7,490 restricted stock units in BioMarin Pharmaceutical Inc. as part of a standard equity grant.

Summary

• Director Ian T. Clark was granted 7,490 restricted stock units (RSUs) on June 2, 2026.
• The transaction resulted in a total direct beneficial ownership of 14,490 shares of BioMarin Pharmaceutical Inc. (BMRN) common stock.
• The shares were acquired at no cost as part of an equity compensation arrangement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation.

Positives

• Alignment of director interests with shareholders through increased equity ownership.

Negatives

• None identified.

Risks

• Standard market risks associated with equity holdings in the biotechnology sector.

Future Outlook

No specific forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology industry to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard compensation practices for mid-to-large cap pharmaceutical companies.
• The transaction size is typical for director-level equity compensation packages.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation.

Next Steps

• Vesting of the restricted stock units according to the company's equity incentive plan.

Key Dates

Keywords

BioMarin, BMRN, Insider Trading, Form 4, Director Compensation, Biotechnology